10-K: America Great Health Reports Increased Sales but Widens Net Loss in Fiscal Year 2024

America Great Health's 10-K filing reveals increased sales revenue for fiscal year 2024, but also a larger net loss due to rising operating expenses and cost of goods sold, alongside ongoing concerns about the company's ability to continue as a going concern.

Summary

• America Great Health's Form 10-K filing covers the fiscal year ended June 30, 2024.
• The company reported sales of $294,670 for the year ended June 30, 2024, compared to $204,308 for the previous year.
• The cost of goods sold increased to $124,920 in 2024 from $35,720 in 2023.
• Operating expenses also increased from $661,232 in 2023 to $952,450 in 2024, driven by higher payroll, travel, advertising, and professional expenses.
• The company's net loss widened to $1,226,362 in 2024 from $777,340 in 2023.
• As of June 30, 2024, the company had a cash balance of $54,943 and a shareholders' deficit of $5,311,599.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• Management is focused on investing in innovative technologies within the healthcare ecosystem, including protein and peptide small molecular drugs, diagnostic and medical devices, cell therapy, and regenerative medicine.
• The company has entered into several agreements, including international agency and technology contracts with Yunan Yunchi Xiai Trading Co. Ltd. and a product project cooperation framework with Aide Huhuan (Chengdu) Enterprise Management, Co. Ltd.
• The company's internal controls over financial reporting were deemed ineffective due to a lack of segregation of duties and insufficient board representation.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the increasing net loss, going concern warning, and ineffective internal controls, despite the increase in sales revenue.

Positives

• The company's sales increased from $204,308 to $294,670, indicating some growth in revenue generation.
• The company is actively pursuing new business opportunities through agreements with Chinese companies, which could lead to future revenue growth.
• The company is focused on investing in innovative technologies within the healthcare ecosystem, which could lead to the development of valuable products and services.

Negatives

• The company's net loss increased from $777,340 to $1,226,362, indicating a deterioration in profitability.
• Operating expenses increased significantly, outpacing revenue growth and contributing to the larger net loss.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern, raising concerns about its long-term viability.
• The company's internal controls over financial reporting were deemed ineffective, increasing the risk of errors or fraud in financial reporting.

Risks

• The company's recurring losses and shareholders' deficit raise substantial doubt about its ability to continue as a going concern.
• The company's reliance on loans and advances from its majority shareholder for working capital creates a risk of financial instability.
• The company's ineffective internal controls over financial reporting increase the risk of errors or fraud in financial reporting.
• The company's expansion into new markets and technologies involves risks associated with cross-border business and the development of new products and services.

Future Outlook

The company plans to continue as a going concern by achieving profitable operations and raising necessary capital. Management is focused on investing in innovative technologies within the healthcare ecosystem and expanding its market reach through agreements with Chinese companies.

Management Comments

• Our mission is to invest in innovative technologies, integrated with business development in the healthcare ecosystem.
• We are focused on protein and peptide small molecular drugs research and development, diagnostic and medical devices with AI cloud computing, cell therapy and regenerational medicine and supplements manufacturing and sales.

Industry Context

The company operates in the health industry, which is experiencing rapid growth in the Asia Pacific region due to improved living standards and increased demand for healthcare products and services. The company is attempting to capitalize on this trend by making acquisitions and forming partnerships with companies in the region.

Comparison to Industry Standards

• It's difficult to directly compare America Great Health's performance to industry standards due to its unique business model and focus on early-stage technologies.
• However, the company's increasing net loss and concerns about its ability to continue as a going concern are significant red flags that warrant further investigation.
• Companies like Novavax, which faced going concern warnings, illustrate the challenges in the biotech sector, where significant R&D investments and regulatory hurdles can impact financial stability.
• Unlike established pharmaceutical giants such as Johnson & Johnson or Pfizer, America Great Health lacks a diversified product portfolio and consistent revenue streams, making it more vulnerable to financial distress.
• The company's reliance on related-party loans is also a deviation from industry norms, where companies typically rely on traditional financing methods such as bank loans or equity offerings.

Related Party Transactions

• During the year ended June 30, 2024, the company's current majority shareholder advanced $969,868 to the company as working capital and the company repaid $276,596 to the shareholder.
• As of June 30, 2024 and 2023, the company owed its current shareholder of $1,110,196 and $425,142 respectively.
• The advances are non-interest bearing and are due on demand.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees face uncertainty about their job security due to the company's financial challenges.
• Customers and suppliers may be hesitant to do business with the company due to its financial instability.
• Creditors face increased risk of not being repaid due to the company's financial challenges.

Next Steps

• The company needs to secure additional sources of capital to address its liquidity issues.
• The company needs to improve its internal controls over financial reporting to ensure the accuracy and reliability of its financial statements.
• The company needs to execute its business plan and generate profitable operations to ensure its long-term viability.

Key Dates

Keywords

healthcare, financial results, going concern, internal controls, net loss, sales, biotechnology, pharmaceuticals, regenerative medicine, China, agreements, equity investment